Efficacy of Aprepitant for Hematology and Oncology.

Phase 2

• Conditions: Hematological malignancies

• Registration Number: JPRN-UMIN000009702
• Lead Sponsor: Kyoto University Hospital,Department of Hematology and Oncology

Brief Summary

Frequency of nausea and vomitting decreased with the addition of aprepitant.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-01-20
• Study Completion: 2014-01-21
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1. chemotherapy within 6 days before study day 1 or between days 1 to 6. 2.Antiemetic therapy prior to 48 hr of chemotherapy. 3.Corticosteroids therapy within 72 hr before study day 1 or duration of study 4.Radiation therapy to the abdomen or pelvis within 6 days before study day 1 or duration of study 5.known central nervous system malignancy 6.following drug therapy within 6 days before study day 1 - clarithromycin, ketoconazole, itraconazole - 7. following drug therapy within 4 weeks before study day 1 - barbiturate, rifampicin, phenytoin, carbamazepine - 8. pregnant, nursing or possibly pregnant women 9.Patients judged inappropriate for this study by physicians

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The difference of the incidence of nausea and vomiting

Secondary Outcome Measures

Name	Time	Method
The proportion of patients with Complete Response (no emesis and no rescue therapy) in the overall phase (0-120 hour after administration of antitumor agent). The proportion of patients with Complete Response ( no emesis and no rescue therapy ) in Day 1 or Day 2 - Day 5.